Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 226,117,950 papers from all fields of science
Search
Sign In
Create Free Account
thermozymocidin
Known as:
2-amino-2-hydroxymethyl-3,4-dihydroxy-14- oxoeicos-6-enoic acid
, SPI-1 inhibitor
, myriocin
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
4 relations
Broader (3)
Antifungal Agents
Fatty Acids, Monounsaturated
Immunosuppressive Agents
Narrower (1)
ISP-1 suppressant
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Sng1 associates with Nce102 to regulate the yeast Pkh-Ypk signalling module in response to sphingolipid status.
Sara García-Marqués
,
F. Randez-Gil
,
Sebastien Dupont
,
E. Garre
,
J. Prieto
Biochimica et Biophysica Acta
2016
Corpus ID: 25067403
2014
2014
Ceramides mediate cigarette smoke-induced metabolic disruption in mice.
Mikayla O. Thatcher
,
Trevor S. Tippetts
,
+8 authors
B. Bikman
American Journal of Physiology. Endocrinology and…
2014
Corpus ID: 12299016
Cigarette smoke exposure increases lung ceramide biosynthesis and alters metabolic function. We hypothesized that ceramides are…
Expand
2014
2014
Sphingolipid levels crucially modulate lateral microdomain organization of plasma membrane in living yeast
J. Večeř
,
P. Veselá
,
J. Malínský
,
P. Heřman
FEBS Letters
2014
Corpus ID: 41761905
2014
2014
Myriocin induces apoptotic lung cancer cell death via activation of DR4 pathway
Kyung Eun Choi
,
Y. Jung
,
+9 authors
J. Hong
Archives of pharmacal research
2014
Corpus ID: 22283134
It has been known that myriocin inhibits melanoma growth. However, the effects and action mechanisms of myriocin on lung cancer…
Expand
2013
2013
Ceramide inhibitor myriocin restores insulin/insulin growth factor signaling for liver remodeling in experimental alcohol‐related steatohepatitis
Diana Lizarazo
,
Valerie Zabala
,
M. Tong
,
L. Longato
,
S. Monte
Journal of Gastroenterology and Hepatology
2013
Corpus ID: 10264828
Alcohol‐related liver disease (ALD) is mediated in part by insulin resistance. Attendant dysregulation of lipid metabolism…
Expand
2012
2012
Sphingosine 1-Phosphate Receptor 1 as a Useful Target for Treatment of Multiple Sclerosis
K. Chiba
,
K. Adachi
Pharmaceuticals
2012
Corpus ID: 17260331
Sphingosine 1-phosphate (S1P), a lysophospholipid mediator, is generated from sphingosine by sphingosine kinases and binds five…
Expand
2007
2007
De Novo Sphingolipid Synthesis Is Essential for Viability, but Not for Transport of Glycosylphosphatidylinositol-Anchored Proteins, in African Trypanosomes
S. Sutterwala
,
Caleb H. Creswell
,
Sumana Sanyal
,
A. Menon
,
J. Bangs
Eukaryotic Cell
2007
Corpus ID: 2646903
ABSTRACT De novo sphingolipid synthesis is required for the exit of glycosylphosphatidylinositol (GPI)-anchored membrane proteins…
Expand
2004
2004
Disruption of sphingolipid homeostasis by myriocin, a mycotoxin, reduces thymic and splenic T-lymphocyte populations.
V. Johnson
,
Q. He
,
M. Osuchowski
,
Raghubir P. Sharma
Toxicology
2004
Corpus ID: 34430259
Highly Cited
1994
Highly Cited
1994
Fungal metabolites. Part 12. Potent immunosuppressant, 14-deoxomyriocin, (2S,3R,4R)-(E)-2-amino-3,4-dihydroxy-2-hydroxymethyleicos-6-enoic acid and structure-activity relationships of myriocin…
T. Fujita
,
K. Inoue
,
+7 authors
T. Okumoto
Journal of antibiotics (Tokyo. )
1994
Corpus ID: 34327185
In order to investigate the structure-activity relationships, fourteen derivatives of myriocin ((2S,3R,4R)-(E)-2-amino-3,4…
Expand
1994
1994
Total synthesis of a novel immunosuppressant, myriocin (thermozymocidin, ISP-I), and Z-myriocin.
M. Yoshikawa
,
Y. Yokokawa
,
Y. Okuno
,
N. Murakami
Chemical and pharmaceutical bulletin
1994
Corpus ID: 42303372
Myriocin (thermozymocidin, ISP-I), which was known to exhibit several interesting biological properties such as potent…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE